Skip to main content

Table 4 The incidence of TRAEs in GC group

From: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma

 

GC(n = 12)

Grade = 1

Grade = 2

Grade = 3

Patients with TRAEs

9(75.0%)

1(8.3%)

2(16.7%)

leukopenia

5(41.7%)

0

1(8.3%)

Anemia

7(58.3%)

0

0

thrombocytopenia

3(25.0%)

0

0

elevated creatinine

2(16.7%)

0

0

Nausea/vomiting

8(66.7%)

1(8.3%)

1(8.3%)

Diarrhea

2(16.7%)

0

0

Pruritus

2(16.7%)

0

0

Fatigue

3(25.0%)

0

0

  1. GC: gemcitabine plus cisplatin
  2. TRAEs: treatment related adverse events
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us